MA55090A - Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs - Google Patents

Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs

Info

Publication number
MA55090A
MA55090A MA055090A MA55090A MA55090A MA 55090 A MA55090 A MA 55090A MA 055090 A MA055090 A MA 055090A MA 55090 A MA55090 A MA 55090A MA 55090 A MA55090 A MA 55090A
Authority
MA
Morocco
Prior art keywords
prophylactic
truncated
diagnostic
binding
medicinal product
Prior art date
Application number
MA055090A
Other languages
English (en)
Inventor
Marito Araki
Yoshihiko Kihara
Norio Komatsu
Original Assignee
Juntendo Educational Found
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juntendo Educational Found, Meiji Seika Pharma Co Ltd filed Critical Juntendo Educational Found
Publication of MA55090A publication Critical patent/MA55090A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4727Calcium binding proteins, e.g. calmodulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
MA055090A 2019-02-28 2020-02-28 Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs MA55090A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019036119 2019-02-28

Publications (1)

Publication Number Publication Date
MA55090A true MA55090A (fr) 2022-01-05

Family

ID=72239809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055090A MA55090A (fr) 2019-02-28 2020-02-28 Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs

Country Status (12)

Country Link
EP (1) EP3932952A4 (fr)
JP (1) JP7527589B2 (fr)
KR (1) KR20210134705A (fr)
CN (1) CN113508140B (fr)
AU (1) AU2020227989A1 (fr)
BR (1) BR112021016619A2 (fr)
CA (1) CA3130909A1 (fr)
IL (1) IL285267A (fr)
MA (1) MA55090A (fr)
MX (1) MX2021010404A (fr)
SG (1) SG11202108494YA (fr)
WO (1) WO2020175689A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116322763A (zh) * 2020-08-27 2023-06-23 学校法人顺天堂 抗切断型突变calr-cd3双特异性抗体及医药组合物
CN114395037B (zh) * 2021-11-03 2023-01-17 深圳市人民医院 靶向钙网蛋白的纳米抗体及其应用
GEAP202416555A (en) 2021-12-08 2024-10-28 Incyte Corp Anti-mutant calreticulin (calr) antibodies and uses thereof
AU2022416990A1 (en) * 2021-12-13 2024-07-18 Adelaide university Antibodies to mutant calreticulin and uses thereof
TW202342097A (zh) 2022-02-25 2023-11-01 學校法人順天堂 抗突變calr抗體與其他藥劑組合而成之醫藥
CN117003866B (zh) * 2023-08-23 2025-06-06 复旦大学附属华山医院 一种抗calr突变蛋白抗体、制备方法及检测试剂盒
WO2026013015A1 (fr) * 2024-07-09 2026-01-15 Merus N.V. Fractions de liaison multispécifiques comprenant des domaines de liaison à calr et cd3

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (fr) 1992-03-24 1994-09-30 Kevin S. Johnson Methodes de production d'elements formant des paires specifiques de liaison
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (fr) 1993-12-03 1995-06-08 Medical Research Council Proteines et peptides de liaison recombines
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
MX348980B (es) * 2013-09-16 2017-07-05 Cemm-Forschungszentrum Für Molekulare Medizin Gmbh Calreticulina mutante para la diagnosis de malignidades mieloides.
EP3029060A1 (fr) * 2014-12-01 2016-06-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Plantes supérieures génétiquement modifiées avec photosynthèse améliorée et/ou production de biomasse, procédés et utilisations associées
WO2016087514A1 (fr) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anticorps anticalréticuline mutante et leur utilisation dans le diagnostic et la thérapie de tumeurs malignes myéloïdes
JP2017062127A (ja) 2015-09-24 2017-03-30 学校法人順天堂 骨髄増殖性腫瘍予防又は治療薬のスクリーニング方法

Also Published As

Publication number Publication date
EP3932952A1 (fr) 2022-01-05
SG11202108494YA (en) 2021-09-29
MX2021010404A (es) 2021-09-14
US20220098290A1 (en) 2022-03-31
KR20210134705A (ko) 2021-11-10
IL285267A (en) 2021-09-30
EP3932952A4 (fr) 2022-11-30
CN113508140B (zh) 2024-11-19
AU2020227989A1 (en) 2021-09-09
BR112021016619A2 (pt) 2021-11-03
WO2020175689A1 (fr) 2020-09-03
CA3130909A1 (fr) 2020-09-03
JPWO2020175689A1 (fr) 2020-09-03
JP7527589B2 (ja) 2024-08-05
CN113508140A (zh) 2021-10-15

Similar Documents

Publication Publication Date Title
MA55090A (fr) Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3612566A4 (fr) Anticorps antagonistes de cd 14 pour le traitement de maladies neurodégénératives
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
EP2860188A4 (fr) Polypeptides et anticorps pour le traitement d'une infection par le vbh et maladies associées
EP3645040A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
MA33989B1 (fr) Formulation d'anticorps et régimes thérapeutiques
MA44763A (fr) Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang
EP2652506A4 (fr) Utilisation d'anticorps anti-cxcl16 et anti-cxcr6 pour le traitement ou la détection du cancer
EP3712170A4 (fr) Anticorps cd96, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée
MA54089A (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés
LT2013015A (lt) Farmacinės kompozicijos
EP3883602A4 (fr) Antigènes peptidiques de la protéine tau et anticorps se liant à ceux-ci pour le traitement des tauopathies
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
EP2524693A4 (fr) Produit pharmaceutique destiné au traitement prophylactique ou thérapeutique de troubles accompagnés d'une angiogenèse oculaire et/ou d'une perméabilité vasculaire oculaire supérieure à la normale
EP3502248A4 (fr) Anticorps dirigés contre hmgb1 et composition les comprenant pour le traitement ou la prévention de la maladie d'alzheimer
EP3528820A4 (fr) Nouvelles formulations liposomales pegylées d'apeline pour le traitement de maladies liées au système cardiovasculaire
EP3877418A4 (fr) Schéma posologique d'anticorps anti-tigit pour le traitement du cancer
MA52485A (fr) Combinaisons de variants d'anticorps et utilisations associées
EP4079761A4 (fr) Conjugué anticorps anti-cea-analogue d'exatécan et utilisation pharmaceutique de celui-ci
EP3326640A4 (fr) Application de la protéine de moule à action adhésive pour le traitement et la prévention de maladies associées à la mélanine
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc